JPMorgan Chase & Co’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-176,956
| Closed | -$1.7M | – | 6697 |
|
|
2024
Q4 | $1.7M | Buy |
176,956
+114,008
| +181% | +$1.09M | ﹤0.01% | 3494 |
|
|
2024
Q3 | $180K | Buy |
62,948
+32,785
| +109% | +$93.8K | ﹤0.01% | 4504 |
|
|
2024
Q2 | $88.1K | Sell |
30,163
-48,362
| -62% | -$141K | ﹤0.01% | 4666 |
|
|
2024
Q1 | $250K | Buy |
78,525
+32,402
| +70% | +$103K | ﹤0.01% | 4344 |
|
|
2023
Q4 | $155K | Sell |
46,123
-16,770
| -27% | -$56.3K | ﹤0.01% | 4570 |
|
|
2023
Q3 | $150K | Buy |
62,893
+5,458
| +10% | +$13K | ﹤0.01% | 4391 |
|
|
2023
Q2 | $101K | Buy |
57,435
+55,686
| +3,184% | +$98K | ﹤0.01% | 4631 |
|
|
2023
Q1 | $6K | Sell |
1,749
-29,475
| -94% | -$101K | ﹤0.01% | 5364 |
|
|
2022
Q4 | $165K | Sell |
31,224
-81,963
| -72% | -$433K | ﹤0.01% | 4292 |
|
|
2022
Q3 | $400K | Sell |
113,187
-120,997
| -52% | -$428K | ﹤0.01% | 3861 |
|
|
2022
Q2 | $604K | Sell |
234,184
-84,492
| -27% | -$218K | ﹤0.01% | 3771 |
|
|
2022
Q1 | $1.43M | Buy |
318,676
+20,894
| +7% | +$93.6K | ﹤0.01% | 3402 |
|
|
2021
Q4 | $2.03M | Sell |
297,782
-56,283
| -16% | -$383K | ﹤0.01% | 3221 |
|
|
2021
Q3 | $2.58M | Buy |
354,065
+41,371
| +13% | +$302K | ﹤0.01% | 3007 |
|
|
2021
Q2 | $3.13M | Buy |
312,694
+1,832
| +0.6% | +$18.4K | ﹤0.01% | 2944 |
|
|
2021
Q1 | $2.97M | Buy |
310,862
+304,917
| +5,129% | +$2.91M | ﹤0.01% | 2991 |
|
|
2020
Q4 | $65K | Buy |
5,945
+939
| +19% | +$10.3K | ﹤0.01% | 4394 |
|
|
2020
Q3 | $45K | Buy |
+5,006
| New | +$45K | ﹤0.01% | 4315 |
|